Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 26Gemcitabine 22Fluorouracil 17Capecitabine 16Leucovorin 15pembrolizumab 14Docetaxel 14Cisplatin 13Bevacizumab 12Radiotherapy 8Paclitaxel 8Irinotecan 8Trastuzumab 7Pemetrexed 6Carboplatin 6130-nm albumin-bound paclitaxel 6durvalumab 5cemiplimab 5Erlotinib Hydrochloride 5Sunitinib 4Ramucirumab 4Metformin 4Gefitinib 4trastuzumab deruxtecan 3tislelizumab 3cabozantinib 3atezolizumab 3Taxes 3Sorafenib 3Panitumumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma × Erythrocyte Count × Clear all
NCT02195180 2018-07-27

Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma

ERYtech Pharma

Phase 2 Completed
141 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡